Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Bortezomib in Relapsed/Refractory Multiple Myeloma
NCT01695330Phase 2Terminated
- Sponsor
- ONCOtherapeutics
- Start
- May 2012
- Primary completion
- Oct 2015
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in multiple myeloma (MM), sponsored by ONCOtherapeutics. Started May 2012; status: terminated.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01695330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01695330.